CC-2850: A Pan-Genotypic Preclinical Nucleoside Lead

CC-2850 is a novel pan-genotypic nucleoside prodrug with similar HCV potency and cytotoxicity profile as sofosbuvir and delivers higher levels of the active metabolite (nucleoside 5’-triphosphate) compared to sofosbuvir.

Our objective is to develop novel nucleoside analog polymerase inhibitors

Traits we target for our inhibitors include:

  • Potent and selective
  • Non-toxic
  • High barrier to drug resistance
  • No drug-drug interactions

CC-2850 Status

  • Preclinical characterization is ongoing to enable regulatory filing
  • Phase 1 study scheduled for 2017
Viral Disease Lead Discovery Lead Optimization Preclinical Regulatory Filing Phase 1
Hepatitis C CC-2850 (Nuc)
Lead Discovery Phase complete
Lead Optimization Phase complete
Preclinical Phase in progress
Regulatory Filing Phase not started
Phase 1 Phase not started